Determination of liver fibrosis stages in Egyptian chronic hepatitis B patients by a noninvasive tool

Autor: Serag WM; Department of Chemistry, Faculty of Science, Suez University, Suez, Egypt, Mohamed MM; Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, Egypt, Elsayed BE; National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt, Abd-Elhamed SM; Chemical Administration, Suez, Egypt
Jazyk: angličtina
Zdroj: Turkish journal of medical sciences [Turk J Med Sci] 2019 Aug 08; Vol. 49 (4), pp. 1145-1150. Date of Electronic Publication: 2019 Aug 08.
DOI: 10.3906/sag-1812-165
Abstrakt: Background/aim: Hepatitis B virus (HBV) infection is the leading cause of liver fibrosis (LF). The prognosis and management of patients with chronic hepatitis B virus depend on the amount and progression of liver fibrosis. Angiopoietin-like protein 2 (Angptl2) is not only a chronic inflammatory mediator, but also a tissue-remodeling factor. The aim of this study is to explore the predictive value of Angptl2 in different fibrosis stages in patients chronically infected with HBV.
Materials and Methods: Eighty patients with chronic HBV infection undergoing Fibroscan were included. Serum concentrations of Angptl2 were detected using a commercial ELISA kit.
Results: Angptl2 levels were significantly associated with liver fibrosis stages (P = 0.02). The area under the curve (AUC) of Angptl2 for distinguishing patients who showed significant fibrosis (F2–F4) was70.2%. Angptl2 with fibrosis-4 (FIB-4) and Angptl2 with AST/platelets ratio (APRI) performed best with an AUC of 92.5%.
Conclusion: In patients with chronic HBV infection, Angptl2 level represents a potential biomarker independently associated with fibrosis stages. The combination of Angptl2 with FIB-4 or Angptl2 with APRI performed better than the existing models for diagnosing significant fibrosis.
(This work is licensed under a Creative Commons Attribution 4.0 International License.)
Databáze: MEDLINE
Externí odkaz: